Sermonix to Present Poster on Oncologists’ Perception of Sexual Intimacy Issues in Treatment of Metastatic Breast Cancer at 2019 North American Menopause Society Annual Meeting
25 sept. 2019 10h00 HE
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female-specific oncology products in the...
Sermonix Doses First Patient in Phase 2 Clinical Trial of Lasofoxifene for Targeted Precision Medicine Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer
23 sept. 2019 10h01 HE
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female-specific oncology products in the...
Sermonix Pharmaceuticals Closes US$26 Million Series A Financing Round Led by WILD Family Office
31 juil. 2019 10h00 HE
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, July 31, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female-specific oncology products, today...
Resource Directory Built for Metastatic Breast Cancer Community
16 juil. 2019 09h00 HE
|
Patient Advocate Foundation
Hampton, VA, July 16, 2019 (GLOBE NEWSWIRE) -- Patient Advocate Foundation (PAF) has launched the Metastatic Breast Cancer Resource Directory, a new patient-friendly search tool designed to...
Sermonix Poster Presentation at 2019 ASCO Annual Meeting Demonstrates Promise for Lasofoxifene in Treating ER+ Metastatic Breast Cancer Patients With ESR1 Mutations
03 juin 2019 10h43 HE
|
Sermonix Pharmaceuticals LLC
Sermonix-sponsored University of Chicago preclinical investigation demonstrated: Lasofoxifene alone was significantly more effective than fulvestrant at inhibiting metastasis of both MCF7-Y537S and...
Sermonix Receives FDA Fast Track Designation for Investigational Drug Lasofoxifene
28 mai 2019 10h00 HE
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, May 28, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development of female-specific oncology products, today...
Sermonix to Present Poster on ‘Lasofoxifene as a Potential Treatment for ER+ Metastatic Breast Cancer’ at 2019 ASCO Annual Meeting
07 mai 2019 10h00 HE
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, May 07, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology...
Sermonix Pharmaceuticals Adds Three New Members to Its Board of Directors
23 avr. 2019 10h00 HE
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, April 23, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific...
Sermonix to Present Poster at ENDO 2019 on Lasofoxifene’s ‘Potent Anti-Tumor Activity’ in ESR1 Hormone-Resistant Breast Cancer
04 mars 2019 10h00 HE
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, March 04, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific...
Too Young for Breast Cancer? Not at this Conference
12 févr. 2019 07h00 HE
|
Young Survival Coalition
New York, NY, Feb. 12, 2019 (GLOBE NEWSWIRE) -- The Young Survival Coalition (YSC) will host more than 600 young breast cancer survivors, co-survivors and healthcare providers in Austin, Texas,...